|
Gene: C5orf56 |
Gene summary for C5ORF56 |
Gene summary. |
Gene information | Species | Human | Gene symbol | C5orf56 | Gene ID | 441108 |
Gene name | IRF1 antisense RNA 1 | |
Gene Alias | C5orf56 | |
Cytomap | 5q31.1 | |
Gene Type | ncRNA | GO ID | GO:0003674 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
441108 | C5orf56 | LZE22T | Human | Esophagus | ESCC | 2.03e-02 | 2.37e-01 | 0.068 |
441108 | C5orf56 | LZE24T | Human | Esophagus | ESCC | 8.59e-22 | 6.75e-01 | 0.0596 |
441108 | C5orf56 | P1T-E | Human | Esophagus | ESCC | 2.71e-03 | 1.60e-01 | 0.0875 |
441108 | C5orf56 | P2T-E | Human | Esophagus | ESCC | 3.20e-19 | 3.91e-01 | 0.1177 |
441108 | C5orf56 | P5T-E | Human | Esophagus | ESCC | 2.38e-04 | 9.01e-02 | 0.1327 |
441108 | C5orf56 | P8T-E | Human | Esophagus | ESCC | 7.37e-14 | 2.20e-01 | 0.0889 |
441108 | C5orf56 | P9T-E | Human | Esophagus | ESCC | 1.17e-07 | 2.10e-01 | 0.1131 |
441108 | C5orf56 | P10T-E | Human | Esophagus | ESCC | 3.48e-07 | 5.71e-02 | 0.116 |
441108 | C5orf56 | P11T-E | Human | Esophagus | ESCC | 6.51e-13 | 5.42e-01 | 0.1426 |
441108 | C5orf56 | P12T-E | Human | Esophagus | ESCC | 1.01e-09 | 1.76e-01 | 0.1122 |
441108 | C5orf56 | P15T-E | Human | Esophagus | ESCC | 7.09e-06 | 1.65e-01 | 0.1149 |
441108 | C5orf56 | P16T-E | Human | Esophagus | ESCC | 3.14e-08 | 6.57e-02 | 0.1153 |
441108 | C5orf56 | P17T-E | Human | Esophagus | ESCC | 3.26e-06 | 3.44e-01 | 0.1278 |
441108 | C5orf56 | P19T-E | Human | Esophagus | ESCC | 1.89e-03 | 2.39e-01 | 0.1662 |
441108 | C5orf56 | P20T-E | Human | Esophagus | ESCC | 2.17e-19 | 6.01e-01 | 0.1124 |
441108 | C5orf56 | P21T-E | Human | Esophagus | ESCC | 9.67e-10 | 1.66e-01 | 0.1617 |
441108 | C5orf56 | P22T-E | Human | Esophagus | ESCC | 1.82e-05 | 1.06e-01 | 0.1236 |
441108 | C5orf56 | P23T-E | Human | Esophagus | ESCC | 9.75e-16 | 3.45e-01 | 0.108 |
441108 | C5orf56 | P24T-E | Human | Esophagus | ESCC | 7.08e-18 | 5.22e-01 | 0.1287 |
441108 | C5orf56 | P26T-E | Human | Esophagus | ESCC | 1.93e-04 | 5.32e-02 | 0.1276 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | |
Endometrium | AEH | |
Endometrium | EEC | |
Prostate | BPH | |
Prostate | Tumor |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C5orf56 | deletion | Frame_Shift_Del | novel | c.107delN | p.Leu37SerfsTer86 | p.L37Sfs*86 | Q8N8D9 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
C5orf56 | SNV | Missense_Mutation | c.181G>C | p.Glu61Gln | p.E61Q | Q8N8D9 | protein_coding | deleterious_low_confidence(0) | benign(0.076) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
C5orf56 | SNV | Missense_Mutation | c.367G>A | p.Glu123Lys | p.E123K | Q8N8D9 | protein_coding | tolerated_low_confidence(0.12) | benign(0.01) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
C5orf56 | SNV | Missense_Mutation | novel | c.293T>C | p.Leu98Pro | p.L98P | Q8N8D9 | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.899) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5orf56 | SNV | Missense_Mutation | novel | c.110N>G | p.Leu37Arg | p.L37R | Q8N8D9 | protein_coding | tolerated_low_confidence(0.06) | benign(0.271) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
C5orf56 | SNV | Missense_Mutation | novel | c.215G>A | p.Arg72Lys | p.R72K | Q8N8D9 | protein_coding | tolerated_low_confidence(0.18) | benign(0.173) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5orf56 | SNV | Missense_Mutation | novel | c.375N>T | p.Gln125His | p.Q125H | Q8N8D9 | protein_coding | deleterious_low_confidence(0) | benign(0.025) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5orf56 | SNV | Missense_Mutation | novel | c.279N>A | p.Phe93Leu | p.F93L | Q8N8D9 | protein_coding | tolerated_low_confidence(0.6) | benign(0) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
C5orf56 | SNV | Missense_Mutation | novel | c.222N>T | p.Trp74Cys | p.W74C | Q8N8D9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.923) | TCGA-55-7227-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | SD |
C5orf56 | SNV | Missense_Mutation | c.245N>T | p.Ser82Leu | p.S82L | Q8N8D9 | protein_coding | tolerated_low_confidence(0.08) | benign(0.211) | TCGA-63-5131-01 | Lung | lung squamous cell carcinoma | Male | Unknown | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |